石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the Notice of Approval for Drug Clinical Trial for Mannitol Sorbitol Injection from the National Medical Products Administration of China, and will carry out the clinical trials for such compound preparation.

The target indications of Mannitol Sorbitol Injection include (i) lowering intracranial pressure and reducing brain volume; (ii) lowering intraocular pressure; and (iii) through osmotic diuresis, prevention and treatment of intraoperative and postoperative acute renal failure and those caused by trauma and drug poisoning.

Both Mannitol and Sorbitol are osmotic diuretics. As a single preparation, both injections have been on the market for many years and there are many approvals for production and registration in China. They are widely used in clinical applications and are used by many patients, and are clinically common drugs, essential drugs and emergency medicines. However, continuous use of 20% Mannitol for more than five times can lead to a reversal of the blood-brain osmotic pressure gradient. Therefore, long-term use of large doses should be avoided to reduce its impact on renal function and electrolytes. Moreover, Mannitol is prone to crystallization or precipitation at low temperatures which is a problem not been fundamentally solved for a long time. Sorbitol is used in China only for the treatment of cerebral edema and glaucoma, or can be used in the treatment of edema and oliguria with normal heart and kidney function. Up to now, there has been no approvals for production and registration for Mannitol Sorbitol Injection as a compound preparation in China.

The compound preparation, which was composed of 15% Mannitol and 5% Sorbitol, can prevent the crystallization and precipitation of mannitol and thus reduce the risk of medication. Also, Mannitol Sorbitol injection improves the convenience of clinical use due to its product stability in various temperature environments of clinical application, and avoids the issue of increased safety risk due to mannitol particles or crystals caused by relatively poor conditions in medical environment and the issue of increased nursing workload. Mannitol Sorbitol Injection has been approved for entering into the market in Japan since 1966, has been widely used in clinical practice for lowering intracranial pressure or as an osmotic diuretic, and except for the risk of acute renal failure when used in large quantities, has not been reported for other serious adverse reactions.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 26 August 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.